Colonoscopy

EQS-News: Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Retrieved on: 
Thursday, December 28, 2023
Patient, Adenoma, CRC, Polyp, Messenger, Biomarker, FDA, Colorectal cancer, Data, Ageing, Trial of the century, Colonoscopy, Cancer, Gene expression, AA

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Key Points: 
  • Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
    BERKELEY, US – MAINZ, Germany – December 5, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today groundbreaking topline results from its eAArly DETECT U.S. clinical study, a multi-center feasibility study assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into a next generation version of ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories.
  • The eAArly DETECT topline results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%.
  • “The eAArly DETECT and ColoFuture study read-outs not only represent an outstanding result for the Company but also for CRC disease treatment and personal healthcare management.

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 16, 2023
Health, Patient, Marketing, Genetic testing, PPV, Conference, Cancer, R, Growth, NPV, Hospital, Colonoscopy, PMA, Food, Colorectal cancer, Mortality, PHI, USD, Trial of the century, Infection, Biomarker, Senior counsel, Update, Commercial, Bank statement, Collection, AA, Insurance, Partnership, Nine Months, BGM, Form 6-K, Genetics, FG, Research, Ageing, CRC, Clinical trial, PCR, Death, FDA, Gene expression, Messenger, HLA, Vaccine, Nursing, Pharmaceutical industry

BERKELEY, Calif. and MAINZ, Germany, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its financial results of the third quarter ending September 30, 2023 and provided a corporate update.

Key Points: 
  • ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023
    BERKELEY, Calif. and MAINZ, Germany, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its financial results of the third quarter ending September 30, 2023 and provided a corporate update.
  • “This past quarter was an important period of progress for the Company highlighted by ColoFuture’s spectacular readout of results.
  • During the quarter, Mainz Biomed established a strategic partnership with Ärztliches Labor Dr. Buhlmann, a respected player in PCR-based analysis.
  • Throughout the third quarter, Mainz Biomed continued to prepare for commencing patient enrollment in the ReconAAsense clinical trial (ClinicalTrials.gov Identifier: NCT05636085).

Dak Prescott Joins Ryan Reynolds’ Maximum Effort and the Colorectal Cancer Alliance to ‘LEAD FROM BEHIND’

Retrieved on: 
Friday, December 8, 2023
Oncology, Philanthropy, Entertainment, Health, Celebrity, Other Philanthropy, Other Health, Research, Prevent Cancer Foundation, DNA, Exact Sciences (company), Colorectal cancer, Love, Risk, Disease, Colorectal Cancer Alliance, Multimedia, Patient, NFL, Exact sciences, Blood, Health equity, FIT, Cancer, Diagnosis, Survival, Geography, Poverty, Partnership, Dallas Cowboys, Sport, Colonoscopy, Dairy, Birth control, Pharmaceutical industry, Black

NFL quarterback Dak Prescott of the Dallas Cowboys is teaming up with the nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance), and Ryan Reynolds’ creative agency, Maximum Effort, to LEAD FROM BEHIND.

Key Points: 
  • NFL quarterback Dak Prescott of the Dallas Cowboys is teaming up with the nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance), and Ryan Reynolds’ creative agency, Maximum Effort, to LEAD FROM BEHIND.
  • “Losing my mother to colon cancer was devastating, and no one should have to go through that,” said Prescott.
  • “I’d like to thank Dak for joining Rob McElhenney, Terry Crews, and me in helping raise awareness for dropping your drawers,” said Maximum Effort Co-founder Ryan Reynolds.
  • "The mission of the Alliance is to end colorectal cancer in our lifetime,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

UTulsa's Hurricane Ventures announces investments in BPEndo, Titan Intake

Retrieved on: 
Monday, December 11, 2023
Titan, Entrepreneurship, Venture capital, Food, University of Tulsa, IRD, Investment, Patient, Multimedia, Faculty, Collins College, FDA, Artificial intelligence, Friends, University, Partnership, Growth, Innovation, Physician, Business, Colonoscopy, Philosophy, Cryptocurrency

TULSA, Okla., Dec. 11, 2023 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced two new start-up investments, BPEndo and Titan Intake.

Key Points: 
  • TULSA, Okla., Dec. 11, 2023 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced two new start-up investments, BPEndo and Titan Intake.
  • Hurricane Ventures aims to commercialize intellectual property, create new ventures and attain venture capital funding.
  • "We are excited by the continued momentum of Hurricane Ventures," said Chris Wright, director of UTulsa's Center for Innovation & Entrepreneurship.
  • Created in partnership with 46 Venture Capital, Hurricane Ventures is a funding catalyst for student, alumni, faculty and staff startups.

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

Retrieved on: 
Thursday, December 7, 2023
Organization, Exact Sciences (company), Colorectal cancer, CRC, Disease, Language, Collection, Patient, Data analysis, FDA, African Americans, Exact sciences, Community, United, USPSTF, FOCUS, FOCUS Program, Education, Hospital, FQHC, Colonoscopy, Health, Transport, Pharmaceutical industry, Medical device, Health insurance, Nursing, Nightclub

Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making healthcare more accessible, with a focus on medically underserved populations.

Key Points: 
  • Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making healthcare more accessible, with a focus on medically underserved populations.
  • Exact Sciences' FOCUS Program provides grant funding to community organizations, health foundations, public health organizations, and advocacy groups working to increase access to CRC screening.
  • Exact Sciences developed Cologuard®, the first and only FDA-approved, noninvasive, multi-target, stool-based DNA screening test that people can use at home.
  • Since making the test available in 2014, Exact Sciences has delivered more than 13 million Cologuard results to patients.

DiaCarta Launches OTC at Home Fecal Occult Blood Test to Complement its ColoScape™ Test

Retrieved on: 
Tuesday, December 5, 2023
Colorectal cancer, Patient, Medicine, Large intestine, FOBT, Blood, US FDA, Cancer, Fecal occult blood, Methylation, Biomarker, OTC, Colonoscopy, Medical imaging

Colorectal cancer is the third most frequent cancer worldwide, emphasizing the critical need for early and effective diagnostic screening methods.

Key Points: 
  • Colorectal cancer is the third most frequent cancer worldwide, emphasizing the critical need for early and effective diagnostic screening methods.
  • DiaCarta is at the forefront of meeting this challenge with the introduction of its advanced iColon FOBT, offering a non-invasive product for early detection of blood in stool at home.
  • The iColon FOBT complements DiaCarta's highly sensitive ColoScape™ Test for qualitative early detection of colorectal cancer-associated mutation and methylation diagnostic biomarkers in circulating blood.
  • "We are excited to introduce our Fecal Occult Blood Test as a significant leap forward in the field of colorectal cancer screening," said Adam (Aiguo) Zhang CEO of DiaCarta.

Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77

Retrieved on: 
Tuesday, December 5, 2023
Capnography, Research, Safety, Anesthesia, Pediatrics, Nursing, Incidence, Chief Dental Officer (Canada), Privacy, Surgeon, Respiratory rate, NORA, Cleveland Clinic, Patient, Stethoscope, Multimedia, Airway obstruction, Algorithm, FDA, Esophagogastroduodenoscopy, Faith, Communication, Software, Speech, Patent, ASA, AI, Intubation, Colonoscopy, Apnea, Friction, Medical device, Dentistry, Anesthesiology

The company's proprietary Airmod system, an active noise-canceling electronic stethoscope that seamlessly integrates with AI, enables continuous monitoring of patients' breathing sounds.

Key Points: 
  • The company's proprietary Airmod system, an active noise-canceling electronic stethoscope that seamlessly integrates with AI, enables continuous monitoring of patients' breathing sounds.
  • In collaboration with Taiwan's major medical centers and teaching hospitals, Heroic Faith has collected over 1.6 million entries of breathing sound data for AI training.
  • Heroic Faith's new General Manager, Yuan-Ren Cheng, has recently updated the company's motto from 'Saving Lives Through Innovation' to 'Saving Lives Through Communication.'
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/saving-lives-through-communicat...
    SOURCE Heroic Faith Medical Science, Inc.

U.S. News to Debut Best Ambulatory Surgery Centers in 2024

Retrieved on: 
Tuesday, November 28, 2023
Ophthalmology, Ambulatory Surgery Center Association, Spine, Hospital, Elective surgery, Urology, Swanson Health Products, Patient, Nursing home, News, Gastroenterology, Partnership, Health care, Colonoscopy, Nursing

WASHINGTON, Nov. 28, 2023 /PRNewswire/ -- U.S. News & World Report, the global authority in health care rankings and consumer advice, today announced the addition of Best Ambulatory Surgery Centers to its annual series of ratings evaluating health care sites. With more than half of all U.S. surgeries categorized as same-day procedures, patients in need of a knee replacement, a colonoscopy or any one of numerous other procedures will now be able to find the objective data they need to choose the same-day specialized surgery center that best meets their health care needs.

Key Points: 
  • WASHINGTON, Nov. 28, 2023 /PRNewswire/ -- U.S. News & World Report, the global authority in health care rankings and consumer advice, today announced the addition of Best Ambulatory Surgery Centers to its annual series of ratings evaluating health care sites.
  • The Best Ambulatory Surgery Centers methodology will combine relevant measures to produce a composite rating for each of several key specialty areas: orthopedics & spine, gastroenterology, urology, and ophthalmology.
  • "These upcoming Ambulatory Surgery Centers ratings rely on our data collaboration with CareJourney and are a meaningful step forward in providing data driven health care insights to consumers," said Sumita Singh, senior vice president and general manager of Healthcare at U.S. News.
  • With its planned release in the second quarter of 2024, Best Ambulatory Surgery Centers complements U.S. News' expanding health rankings and ratings including Best Hospitals, Best Children's Hospitals, Best Senior Living, Best Nursing Homes, Best OTC Medicine & Health Products and Best Diets.

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Monday, November 13, 2023
Shield, DNA, Colorectal cancer, Neoplasm, CRC, Disease, Mortality, Colonoscopy, Patient, Large intestine, Fear, ECLIPSE, Helmy Eltoukhy, Cancer, Samsung Medical Center, Medical imaging

SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Monday, November 13, 2023
Shield, DNA, Colorectal cancer, Neoplasm, CRC, Disease, Mortality, Colonoscopy, Patient, Large intestine, Fear, ECLIPSE, Helmy Eltoukhy, Cancer, Samsung Medical Center, Medical imaging

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."